Table 3.
Ligand | Amino Acids Involved |
---|---|
Cholesterol | V125, E126, L128, W129, *L427*, *L431*, F434, N496, *A497*, A498, T499, V502, *I567*, *A569*, L570, *F573*, L775, D776, L777, I780, Q794, Y801, F987, Y1013, F1017, W1018, Q1020, S1079, V1081, F1147, I1148, Y1151, F1152 |
Dxr | N124, V125, L128, W129, F422, T424, *L427*, L431, G774, L775, D776, L777, F1017, W1018, Y1021, S1079 |
Vemurafenib | V125, W129, N496, *A497*, A498, *A569*, L775, D776, L777, I780, Y801, Y1013, F1017 |
PAH | V125, W129, F434, N496, *A497*, A498, *A569*, L570, L775, D776, L777, I780, F1017, W1018 |
Underlined amino acids have side chains orientated toward the cholesterol or interactions, found by PoseView, with dxr, vemu, and PAH. Amino acids with mutations that result in a damaging phenotype are indicated in bold, between *asterisks* when conserved in the family, and in italics if common with an amino acid listed for the cholesterol.